- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 18.04. | Psyence BioMed gets Nasdaq notice for non-compliance | 1 | Seeking Alpha | ||
| 18.04. | Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | 353 | Newsfile | New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") announced today that it received a notification letter dated April... ► Artikel lesen | |
| 15.04. | Psyence BioMed erhöht Beteiligung an PsyLabs mit 500.000 US-Dollar Investition | 2 | Investing.com Deutsch | ||
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 15.04. | Psyence BioMed boosts stake in PsyLabs with $500k investment | 2 | Investing.com | ||
| 15.04. | Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement | 192 | Newsfile | New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of USD $500,000 into... ► Artikel lesen | |
| 11.04. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 08.04. | Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia | 149 | Newsfile | New York, New York--(Newsfile Corp. - April 8, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the signing of a Letter of Intent (LOI) with Southern Star Research... ► Artikel lesen | |
| 31.03. | Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing | 153 | Newsfile | New York, New York--(Newsfile Corp. - March 31, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") releases the following update:Dear Shareholders and Future Investors:At... ► Artikel lesen | |
| 31.03. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 25.03. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein | 1 | GlobeNewswire (USA) | ||
| 18.03. | Psyence Biomed expands advisory board with psychopharmacology expert | - | Investing.com | ||
| 18.03. | Psyence Biomed erweitert Beirat mit Experten für Psychopharmakologie | 1 | Investing.com Deutsch | ||
| 18.03. | Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein | 254 | Newsfile | New York, New York--(Newsfile Corp. - March 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence Biomed" or the "Company") today announced that it has expanded and further strengthened its Scientific... ► Artikel lesen | |
| 10.03. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board | 172 | GlobeNewswire (Europe) | TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM"... ► Artikel lesen | |
| 04.03. | Psyence Biomedical files to sell 13.81M common shares for holders | 1 | Seeking Alpha | ||
| 24.01. | PSYENCE BIOMEDICAL LTD. - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 23.01. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.12.24 | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.12.24 | Psyence Biomedical Ltd.: Psyence Biomed Announces Closing of $2.0 Million Private Placement | 2 | GlobeNewswire (USA) |
Seite:
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd.: BioLineRx Reports 2024 Financial Results and Provides Corporate Update | - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases -
- Executed license... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 0,412 | +4,70 % | Transcode Therapeutics, Inc. - 8-K, Current Report | ||
| SILEXION THERAPEUTICS | 0,926 | -2,38 % | Silexion Therapeutics Stock Surges 52% On Catalent Collaboration For Cancer Therapy | ||
| MINK THERAPEUTICS | 7,590 | 0,00 % | MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress | NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural... ► Artikel lesen | |
| TEMPUS AI | 53,50 | 0,00 % | Tempus AI: Deal mit Pharma-Riesen - Aktie geht steil | Für den AKTIONÄR ist klar: Künstliche Intelligenz (KI) wird auch in der Forschung und Entwicklung von Medikamenten mittel- bis langfristig sein disruptives Potenzial entfalten. Ein Player, der diesen... ► Artikel lesen | |
| ARCELLX | 63,97 | 0,00 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| QIAGEN | 37,500 | -0,29 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| BIONTECH | 102,50 | +0,29 % | Das ist die Nach-Oster-Chance! Evotec, Bayer, BioNTech, Defence Therapeutics und im Fokus | Donald Trump brüskiert seine internationalen Partner, beleidigt namhafte Amerikaner und entzieht Harvard langjährig zugesagte Fördermittel. Wer hätte das gedacht? Die neue US-Regentschaft entpuppt sich... ► Artikel lesen | |
| EVOTEC | 7,256 | -1,20 % | Evotec mit SONDERMELDUNG: Insider kaufen massenhaft Anteile - Handeln Sie UNBEDINGT vor dem Wochenende! | ||
| VIR BIOTECHNOLOGY | 6,290 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 44,790 | -0,44 % | Merck KGaA unmittelbar vor Milliarden-Deal? Springworks-Aktie springt wieder an | Das Interesse der Darmstädter Merck KGaA an der amerikanischen Biotechnologie-Gesellschaft SpringWorks Therapeutics wird konkreter. Nach einem Bericht des Wall Street Journal (WSJ) bestätigt das DAX-Unternehmen... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 5,100 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| ADMA BIOLOGICS | 22,260 | -0,36 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| TOURMALINE BIO | 17,320 | 0,00 % | Cantor Fitzgerald maintains Overweight on Tourmaline Bio stock | ||
| AVIDITY BIOSCIENCES | 30,940 | 0,00 % | Avidity Biosciences Inc Aktie: Routinebericht des Unternehmens | Avidity Biosciences hat die Rekrutierung für die Biomarker-Kohorte der Phase-1/2-FORTITUDE-Studie für Delpacibart Braxlosiran (Del-Brax) abgeschlossen. Diese Studie zielt auf Patienten mit fazioskapulohumeraler... ► Artikel lesen |
Das Unternehmen PSYENCE BIOMEDICAL LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,027 (+5,78 %) liegt der Kurs bei 0,487 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.
